Compass Pathways is trading 4.2% down at $11.91 on October 1, 2026, with no confirmed catalyst identified for the decline.

  • The latest substantial company news remains the September 9 Phase 3 trial update, not a new event explaining this move.
  • Market indexes showed mixed-to-modest moves, which do not clearly account for the decline.
  • The stock had also fallen in recent sessions, but that pattern alone does not establish a cause.